Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Elocta can be used for all age groups.
Loading your page…
Loading your page…
Hemophilia A
Marketing Authorisation Holder: Swedish Orphan Biovitrum AB (publ)
EMA Authorisation: 18/11/2015
INN: efmoroctocog alfa
AI Drug & Interaction Analysis
Free account required
Ask Osler about Elocta: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.